Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Growth Hormones (Jan 2017)

Posted by Matt Breese on Jan 27, 2017

Find me on:

According to our recent payer coverage analysis for HGH treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access by channel shows how payer pharmacy benefits cover HGH products. Both medicare and health exchange formularies became more restrictive since Q3 of 2016.


Source: MMIT data as of Q3 2016

Trends: See how biobetters can impact the human growth hormone landscape and check out the prescriber perspective on HGH products.

To read the full Reality Check on human growth hormones with key findings on clinical characteristics, HGH drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Market Access, Data & Analytics, Branding & Marketing